Skip to main content
CNSY
NASDAQ Life Sciences

Cerenome Reports Interim ReSPECT-LM Data: No Dose-Limiting Toxicity in First 10 Patients

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.963
Mkt Cap
$7.212M
52W Low
$0.429
52W High
$18.885
52W Position info
125% above low
Off High info
95% below high
Rel. Volume info
10× avg
Market data snapshot near publication time

CNSY has more than doubled off its 52-week low of $0.429 on elevated volume (10× avg).

Summary

Interim ReSPECT-LM data in the first 10 patients showed no dose-limiting toxicities and consistent repeat-dose radiation delivery, with no documented leptomeningeal progression at three or six months among evaluable patients. The findings are preliminary and descriptive, and the company is targeting a randomized Phase 2 study in 2027.


Key Events · Product Development and Regulatory · CNSY

  • Repeat Dosing Clears Safety Hurdle

    No dose-limiting toxicities or adverse events leading to discontinuation occurred in the first 10 patients; the only serious adverse event, shortness of breath in one subject, was deemed unrelated to treatment.

  • Cumulative Activity Exceeds Prior Single Dose

    One patient received three 26.4 mCi doses for 79.2 mCi total, above the 75 mCi highest single administration in the prior single-dose ReSPECT-LM study; that patient's estimated cumulative LM compartment absorbed dose was 207 Gy.

  • Consistent Delivery, Low Marrow Exposure

    Absorbed dose per mCi varied by a median of 8% within patients across repeat administrations, and median blood-derived marrow absorbed dose was 0.023 Gy per administration (range 0.010-0.41 Gy).

  • Early Disease Control Signal

    No LM progression was documented at the three- and six-month landmarks (0/5 evaluable at each); 1 of 4 evaluable patients progressed by nine months. Three patients with detectable baseline CSF tumor cells later had zero tumor cells/mL, two of them still at zero 9.2 and 2.3 months after the first dose.


Analysis · CNSY · Life Sciences

Cerenome's lead therapeutic asset has cleared its first repeat-dosing hurdle. In 10 patients who received multiple intraventricular REYOBIQ doses, there were no dose-limiting toxicities and no discontinuations, and one patient absorbed 79.2 mCi cumulative—above the 75 mCi highest single dose in the earlier study. Radiation delivery was reproducible, with a median 8% within-patient variation, and marrow exposure stayed low at a median 0.023 Gy per administration, the practical gate for escalating dose. The efficacy read is thin and descriptive—0/5 evaluable patients progressed at three and six months, 1 of 4 by nine months, with no PFS or OS claim—but it is directionally consistent with prior Phase 1 data. This matters because the company reported a going-concern warning and held only $879 thousand of cash at Q3, so clinical momentum is the main lever for financing the targeted 2027 randomized Phase 2 study.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CNSY was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.43 to $18.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CNSY - Latest Insights

CNSY
Nov 13, 2026, 5:19 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9601
Real-time Price: $0.9629 info
Change: +$0.0028 (+0.29%) info
Market Cap: $7.212M info
CNSY
Nov 13, 2026, 5:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.970
Real-time Price: $0.9629 info
Change: -$0.0071 (-0.73%) info
Market Cap: $7.212M info
CNSY
Nov 13, 2026, 4:51 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9372
Real-time Price: $0.9629 info
Change: +$0.0257 (+3%) info
Market Cap: $7.212M info
CNSY
Nov 04, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.31
Real-time Price: $0.9629 info
Change: -$0.3471 (-26%) info
Market Cap: $7.212M info
CNSY
Oct 08, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.9629 info
Change: -$0.6671 (-41%) info
Market Cap: $7.212M info